Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients
Open Access
- 15 April 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Arthritis Research & Therapy
- Vol. 22 (1), 1-9
- https://doi.org/10.1186/s13075-020-02164-5
Abstract
Anti-TNF treatment may be useful for the treatment of patients with refractory juvenile dermatomyositis (JDM). The aim of this study was to describe the use of infliximab and adalimumab therapy in juvenile dermatomyositis as an adjunctive treatment. Sixty children recruited to the UK JDM Cohort and Biomarker Study that had received at least 3 months of anti-TNF treatment (infliximab or adalimumab) were studied. Childhood Myositis Assessment Scale (CMAS), Manual Muscle Testing (MMT8) and physician’s global assessment (PGA) were recorded. Skin disease was assessed using the modified skin disease activity score (DAS). Data were analysed using Friedman’s test for repeated measures analysis of variance. Compared to baseline, there were improvements at 6 and 12 months in skin disease (χ2(2) = 15.52, p = 0.00043), global disease (χ2(2) = 8.14, p = 0.017) and muscle disease (CMAS χ2(2) = 17.02, p = 0.0002 and MMT χ2(2) = 10.56, p = 0.005) in infliximab patients. For patients who switched from infliximab to adalimumab, there was improvement in global disease activity (χ2(2) = 6.73, p = 0.03), and trends towards improvement in CMAS, MMT8 and modified DAS. The median initial prednisolone dose was 6 [0–10] mg, and final was 2.5 [0–7.5] mg (p < 0.0001). Fifty-four per cent of patients had a reduction in the number and/or size of calcinosis lesions. Twenty-five per cent switched their anti-TNF treatment from infliximab to adalimumab. 66.7%of the switches were to improve disease control, 26.7% due to adverse events and 6.6% due to patient preference. A total of 13.9 adverse reactions occurred in 100 patient-years, of which 5.7 were considered serious. Reductions in muscle and skin disease, including calcinosis, were seen following treatment with infliximab and adalimumab.Keywords
Funding Information
- Wellcome Trust (085860)
- Action Medical Research (SP4252)
- The Myositis Support Group (n/a)
- Versus Arthritis (14518, 20164)
- The Henry Smith Charity (n/a)
- Great Ormond Street Hospital Charity (V1268)
- The Myositis Association (n/a)
- Cure JM (n/a)
- National Institute for Health Research (n/a)
This publication has 23 references indexed in Scilit:
- The Tumor Necrosis Factor Superfamily of Cytokines in the Inflammatory Myopathies: Potential Targets for TherapyJournal of Immunology Research, 2011
- Efficacy of intravenous Ig therapy in juvenile dermatomyositisAnnals Of The Rheumatic Diseases, 2011
- A national registry for juvenile dermatomyositis and other paediatric idiopathic inflammatory myopathies: 10 years' experience; the Juvenile Dermatomyositis National (UK and Ireland) Cohort Biomarker Study and Repository for Idiopathic Inflammatory MyopathiesRheumatology, 2010
- Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathiesArthritis Care & Research, 2010
- Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosisRheumatology, 2008
- The provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/european League Against Rheumatism Disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: A prospective validation studyArthritis Care & Research, 2007
- International consensus on preliminary definitions of improvement in adult and juvenile myositisArthritis & Rheumatism, 2004
- Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathiesArthritis & Rheumatism, 2004
- Polymyositis and DermatomyositisNew England Journal of Medicine, 1975
- Polymyositis and DermatomyositisNew England Journal of Medicine, 1975